What STOmics does

STOmics is a spatial multi-omics company developing the Stereo-seq (Spatial Enhanced Resolution Omics-Sequencing) platform, the only spatial omics technology globally claimed to deliver both centimeter-level field of view (options exceeding 160 sq cm) and true single-cell/subcellular resolution (500 nm). The technology is built on proprietary DNA nanoball (DNB) patterned chips with Coordinate ID (CID) spatial barcoding originally developed within the BGI/MGI ecosystem. The product portfolio spans four core wet-lab solutions — Stereo-seq Transcriptomics Solution for fresh frozen tissue, Stereo-seq OMNI for FFPE samples (including host-microorganism co-detection), Stereo-seq Large Chip Designs (up to 13cm × 13cm) for whole-organ analysis, and Stereo-CITE for simultaneous whole-transcriptome and 100+ protein profiling — complemented by SAW (Linux-based analysis pipeline) and StereoMap (Windows/MacOS visualization software), plus the MGI-manufactured Go Optical microscope for tissue imaging. The workflow locks into MGI's DNBSEQ-G400RS and DNBSEQ-T7RS sequencing platforms, creating an integrated tissue-to-data chain.

STOmics generates revenue primarily through one-time sales of spatial transcriptomics reagent kits, chips, and consumables distributed globally via MGI Tech (official global distributor across 110+ countries) and a Certified Service Provider network of third-party service labs. Demand generation leans heavily on scientific community channels — grant programs in APAC and Europe, the 19-country STOC Plant consortium, conference presence (EMBO|EMBL, ESSB), and an extensive publication record (60+ papers in Cell, Nature, Science, Cell Research). The customer base is segmented into academic and life science researchers (primary), clinical and translational researchers (primary, particularly for FFPE cohorts), and agricultural and plant science researchers (secondary). Pricing is quote-based and not publicly disclosed.

Founded in 2020 as a spatiotemporal multi-omics platform company (program originated within BGI/MGI in 2019), STOmics was acquired by MGI Tech Co., Ltd. on March 3, 2026 as part of MGI's 'SEQALL+GLI+Omics' strategy, positioning MGI as a single-source provider across short-read sequencing, long-read nanopore sequencing, generative lab intelligence, and spatial omics. The company is operated through GCATbio Co., Ltd., headquartered in Changzhou, Jiangsu, China, and currently employs 101-250 people.

Name

STOmics

Legal name

GCATbio Co., Ltd.

Website

https://en.stomics.tech

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

101–250 employees

Short description

STOmics develops the Stereo-seq spatial multi-omics platform, offering subcellular 500 nm resolution and centimeter-scale field-of-view kits, software, and FFPE solutions for academic, clinical, and agricultural researchers globally through MGI distribution and a Certified Service Provider network.

Ownership category

akta.pro rank

Product category

Spatial Transcriptomics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Spatial transcriptomics
• Multi-omics analysis
• Spatial sequencing
• Tissue imaging
• Molecular profiling

Headquarters

HQ city

Jintan

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Spatial Omics Kits and Reagent Products: STOmics generates revenue primarily through the sale of spatial transcriptomics reagent kits, chips, and related consumables. Products include Stereo-seq Transcriptomics kits, Stereo-seq OMNI FFPE kits, Stereo-seq Large Chip kits, Stereo-CITE proteo-transcriptomics kits, and associated reagents and user manuals. The company also sells sequencing reagents compatible with DNBSEQ-T7RS and DNBSEQ-G400RS platforms.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

STOmics develops and sells spatial transcriptomics reagent kits, chips, instruments, and analysis software based on its proprietary Stereo-seq (Spatial Enhanced Resolution Omics-Sequencing) technology. The offering includes kits for fresh frozen and FFPE tissue samples, large-chip configurations up to 13cm x 13cm, combined proteo-transcriptomics solutions, the Go Optical microscope manufactured by MGI, and the SAW and StereoMap bioinformatics/visualization software suite.

Product overview

STOmics offers the Stereo-seq spatial multi-omics platform, the only spatial technology capable of accessing whole transcriptome at true single-cell resolution with subcellular data achieved through Ultra-HD resolution (500nm) and field of view options over 160 square cm. The product portfolio includes Stereo-seq Transcriptomics Solution for fresh frozen samples, Stereo-seq OMNI Solution for FFPE samples, Stereo-seq Large Chip Designs for large tissue samples, and Stereo-CITE Solution for combined proteo-transcriptomics. Supporting software includes SAW (Stereo-seq Analysis Workflow) for data processing and StereoMap for visualization. The platform integrates with MGI's DNBSEQ sequencing instruments and Go Optical microscope to provide an end-to-end tissue-to-data workflow.

Differentiator

Problem solved

Functional benefit

Brands

• Stereo-seq: Spatial Enhanced Resolution Omics-sequencing technology - a spatial transcriptomics solution that achieves centimeter-level panoramic field of view and cellular resolution with nanoscale subcellular data.
• SAW (Stereo-seq Analysis Workflow)
• StereoMap
• Go Optical
• Stereo-CITE
• Stereo-seq OMNI

Products and services

• Stereo-seq Transcriptomics Solution Spatial transcriptomics reagent kit for unbiased spatial single-cell transcriptomics analysis on fresh frozen (FF) tissue samples with poly-A mRNA capture; supports chip sizes from 0.5cm x 0.5cm to 1cm x 1cm and is compatible with ssDNA, H&E, or immunofluorescence (mIF) staining. For academic and translational researchers in life science and clinical research.
• Stereo-seq OMNI Solution Spatial whole transcriptomics reagent kit for formalin-fixed paraffin-embedded (FFPE) samples using random probe capture, enabling true single-cell resolution spatial gene expression profiling with host-microorganism RNA co-detection capability. For clinical and translational researchers working with FFPE clinical samples.
• Stereo-seq Large Chip Designs Spatial transcriptomics reagent kit for large-sized tissue samples with customizable chip sizes from 1cm x 2cm up to 13cm x 13cm, supporting analysis of entire organs or large tissue sections in a single experiment. For researchers conducting whole-organ atlas and developmental biology studies.
• Stereo-CITE Solution Proteo-transcriptomics reagent kit enabling simultaneous profiling of unbiased whole transcriptome and 100+ high-plex proteins at true single-cell resolution, combining RNA and protein capture on a single chip with DAPI staining. For multi-omic researchers requiring integrated transcriptomic and proteomic spatial data.
• Stereo-seq Analysis Workflow (SAW) Linux command line-based bioinformatics pipeline software that maps sequenced reads back to their spatial locations on tissue sections, generating standardized spatial expression matrices from raw reads. For bioinformatics scientists and researchers running Stereo-seq experiments.
• StereoMap High-definition interactive desktop visualization software for Windows and macOS, enabling visualization of spatial omics data including GEF matrix, image RPI and IPR data, clustering results, cell segmentation, deconvolution annotation, spatial co-expression analysis, and publication-ready HD figure export. For researchers analyzing and presenting Stereo-seq datasets.
• Go Optical Microscope instrument manufactured by MGI and designed for Stereo-seq imaging workflows, using multiple illumination techniques to capture high-resolution tissue images with minimal stitching errors for tissue segmentation. For laboratories performing Stereo-seq spatial omics experiments.

Quantifiable outcome

• Gene capture efficiency improvement of 1x-3x across tested FFPE tissues with Stereo-seq OMNI V1.1
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature10 records

Partnerships

Eight partnerships are on record, tiered core, major, supporting and minor.

• MGI Tech Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 3 March 2026MGI Tech acquired STOmics (along with CycloneSEQ) on March 3, 2026, as part of its 'SEQALL+GLI+Omics' strategy. MGI is the official global distributor of STOmics-related products, leveraging its global marketing network and supply system spanning 110+ countries. Stereo-seq libraries are sequenced exclusively on MGI's DNBSEQ-G400RS and DNBSEQ-T7RS platforms. MGI Australia (subsidiary) is also involved in ongoing patent litigation with Oxford Nanopore regarding CycloneSEQ nanopore sequencers.
• MGI Tech Co., Ltd.coreStrategic or Co-development PartnerSTOmics and MGI jointly launched the Spatial Omics Grant program for the APAC region (Japan, South Korea, Southeast Asia, Middle East), combining STOmics' Stereo-seq technology with MGI's distribution and support infrastructure. The grant offers pilot test packages, kit discounts, and DCS Cloud analysis credits to researchers.
• BGI ResearchcoreStrategic or Co-development PartnerBGI Research is the primary research collaborator behind major Stereo-seq scientific publications including the axolotl brain regeneration atlas (Science, 2022), the macaque brain cell atlas (Cell, 2023), and mouse organogenesis atlas (Cell, 2022). BGI Research led the international team of 17 institutions in 3 countries for the axolotl brain regeneration study.
• STOC Plant Consortium (Plant SpatioTemporal Omics Consortium)majorStrategic or Co-development PartnerSTOC Plant is an international scientific consortium led by researchers from multiple countries (China, Australia, Germany, and others) that leverages STOmics' Stereo-seq platform to build spatiotemporal atlases for major crops including wheat, rice, soybean, and Arabidopsis. The consortium grew from 12 to 19 member countries since its June 2024 founding. It launched the Wheat Spatiotemporal Atlas Project at its 2nd conference in Beijing, November 2025. STOmics (via BGI-Research) serves as the technical platform provider and founding organizer.
• DCS CloudsupportingTechnology or IntegrationSTOmics partners with DCS Cloud, a cloud-based multi-omics data analysis platform, to provide free and discounted standard Stereo-seq data analysis services to kit users. DCS Cloud offers zero-code standard analysis, interactive advanced analysis, low-code personalized analysis, and high-resolution visualization through a web UI. Promotion programs in 2024 and 2025 offered one-time free standard analysis per chip for European Stereo-seq kit purchasers.
• Certified Service Providers (CSP)supportingChannel Partner/ Reseller/ DistributorSTOmics operates a Certified Service Provider (CSP) program enabling third-party labs globally to become certified providers of Stereo-seq spatial omics services. Certified providers receive validated tested data protocols and can offer spatial solutions to their scientific partners. Providers include BGI Tech and SMART BIOTECH as confirmed CSP participants.
• Jinfeng LaboratoryminorStrategic or Co-development PartnerThe first global STOmics center for pathological research was established at Jinfeng Laboratory in Chongqing, China in 2022, serving as a specialized center for Stereo-seq applications in pathological research.
• Qingdao International Cooperation CenterminorStrategic or Co-development PartnerThe first STOmics international cooperation center was established in Qingdao, China in October 2020, marking STOmics' early international expansion efforts.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Illumina: Illumina dominates the sequencing market and has invested in spatial omics partnerships (e.g., with 10x Genomics and others). As the de facto sequencing incumbent, Illumina's installed base creates both an opportunity (if STOmics becomes platform-agnostic) and a barrier (most labs run Illumina sequencers, not DNBSEQ).
• Element Biosciences: Element Biosciences manufactures the AVITI sequencing platform, which competes broadly with MGI's DNBSEQ instruments that STOmics depends on. As an alternative sequencing backbone, Element represents both an adjacent commercial relationship and a competitive threat to STOmics' sequencing-locked workflow.

Direct peers

• Vizgen: Vizgen's MERFISH (MERSCOPE platform) is a single-cell spatial transcriptomics technology competing directly with Stereo-seq, particularly in neuroscience, oncology, and cell biology research. Both target the same academic core labs and translational researchers with high-plex in situ RNA profiling.
• 10x Genomics: 10x Genomics offers the Visium and Xenium spatial transcriptomics platforms, which directly compete with Stereo-seq for the same academic, translational, and pharma customers. Both companies sell consumable kits, chips, instruments, and software for high-resolution spatial gene expression profiling.
• Akoya Biosciences: Akoya offers the CODEX and Phenoptics spatial biology platforms for multiplexed protein and RNA profiling in tissue, overlapping with Stereo-seq's spatial multi-omics value proposition in immuno-oncology and tumor microenvironment research applications.
• Bruker (NanoString CosMx): Bruker acquired NanoString's assets including the CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler, which compete head-to-head with Stereo-seq in single-cell spatial transcriptomics and FFPE-compatible spatial profiling for clinical and translational research customers.

Emerging players

• Resolve Biosciences: Resolve Biosciences' Molecular Cartography platform provides subcellular spatial transcriptomics with comparable resolution to Stereo-seq, targeting similar neuroscience and tumor microenvironment research applications, though with a smaller installed base and narrower product portfolio.
• Curio Bioscience: Curio Bioscience offers spatial transcriptomics solutions (Curio Seeker) for fresh frozen tissue that overlap with Stereo-seq's core spatial transcriptomics use case, particularly for whole-transcriptome single-cell spatial profiling in developmental biology and oncology.
• Rebus Biosystems: Rebus Biosystems develops the Rebel spatial omics platform for high-resolution spatial transcriptomics, competing in the same single-cell spatial gene expression niche as Stereo-seq but with a distinct optical/enzymatic chemistry approach.

Others

• Bio-Techne: Bio-Techne offers RNAscope in situ hybridization and the Lunaphore Comet spatial proteomics platform, providing adjacent spatial biology tools that researchers may combine with or compare against Stereo-seq. Represents an enabling/adjacent player in the broader spatial biology ecosystem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/ST_Omics
• YouTubeyoutube.com/channel/UC_WcTfMWBf8oEJUKMDc4g1g
• LinkedInlinkedin.com/company/bgi-stomics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STOmics